drugset / Trial / NCT05008536
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
Phase 0
Unknown
27 enrolled
Xinqiao Hospital of Chongqing
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to infuse BCMA CAR-NK cells（Umbilical \& Cord Blood (CB) Derived CAR-Engineered NK Cells） to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2022-09-01
- Completion
- 2023-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-BCMA CAR-NK Cells | Cell therapy | 1e+06 cells/kg | — |
| Subject | Anti-BCMA CAR-NK Cells | Cell therapy | 3e+06 cells/kg | — |
| Subject | Anti-BCMA CAR-NK Cells | Cell therapy | 6e+06 cells/kg | — |
| Subject | Anti-BCMA CAR-NK Cells | Cell therapy | 1.2e+07 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |